[go: up one dir, main page]

HK82284A - Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof - Google Patents

Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof

Info

Publication number
HK82284A
HK82284A HK822/84A HK82284A HK82284A HK 82284 A HK82284 A HK 82284A HK 822/84 A HK822/84 A HK 822/84A HK 82284 A HK82284 A HK 82284A HK 82284 A HK82284 A HK 82284A
Authority
HK
Hong Kong
Prior art keywords
cis
hydrogen
formula
methyl
tetrahydro
Prior art date
Application number
HK822/84A
Other languages
English (en)
French (fr)
Inventor
Willard Mckowan Welch
Charles Armon Harbert
Billie Kenneth Koe
Allen Richard Kraska
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK82284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HK82284A publication Critical patent/HK82284A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (10)

1. Cis-isomere Base der Formel und deren pharmazeutisch annehmbare Säureadditionssalze, in der
R1 Wasserstoff oder n-Alkyl mit 1 bis 3 Kohlenstoffatomen,
R2 n-Alkyl mit 1 bis 3 Kohlenstoffatomen, ist,
X und Y jeweils Wasserstoff, Fluor, Chlor, Brom, Trifluormethyl, Alkoxy mit 1 bis 3 Kohlenstoffatomen oder Cyano sind, wobei wenigstens eine der Gruppen X und Y eine andere Bedeutung als Wasserstoff hat, und
W Wasserstoff, Fluor, Chlor, Brom, Trifluormethyl oder Alkoxy mit 1 bis 3 Kohlenstoffatomen ist.
2. Verbindung nach Anspruch 1, wobei die Verbindung entweder das (1 S)-Enantiomer oder das racemische Gemisch des (1 S)-Enantiomeren mit dem entsprechenden (1 R)-Enantiomeren ist.
3. Verbindung nach Anspruch 2, in der R, Wasserstoff oder Methyl, R2 Methyl und Z 3-Chlorphenyl, 4-Chlorphenyl, 4-Methoxyphenyl, 3-Trifluormethyl-phenyl, 4-Trifluormethyl-phenyl, 3,4-Dichlorphenyl, 3-Bromphenyl, 4-Bromphenyl oder 3-Trifluormethyl-4-chlorphenyl ist.
4. Verbindung nach Anspruch 3, in der W Wasserstoff ist.
5. Verbindung nach Anspruch 4, in der Z 3,4-Dichlorphenyl, 3-Trifluormethyl-phenyl, 4-Chlorphenyl, 4-Bromphenyl oder 3-Trifluormethyl-4-chlorphenyl ist.
6. Verbindung nach Anspruch 3, in der R1 Wasserstoff ist.
7. Verbindung nach Anspruch 1, in der die Verbindung
cis-N-Methyl-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N-Methyl-4-(4-bromphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N-Methyl-4-(4-chlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N-Methyl-4-(3-trifluormethyl-phenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N-Methyl-4-(3-trifluormethyl-4-chlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N,N-Dimethyl-4-(4-chlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N,N-Dimethyl-4-(3-trifluormethyl-phenyl)-1,2,3,4-tetrahydro-1-naphthalinamin oder
cis-N-Methyl-4-(4-chlorphenyl)-7-chlor-1,2,3,4-tetrahydro-1-naphthalinamin;
cis-N,N-Dimethyl-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin,
in entweder der (1 S)-enantiomeren oder der racemischen (1 S) (1 R)-Form ist, und deren pharmazeutisch annehmbare Säureadditionssalze.
8. Verbindung nach Anspruch 6, wobei die Verbindung cis-(1S)-N-Methyl-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin ist.
9. Verbindung nach Anspruch 1, wobei die Verbindung das (1 R)-Enantiomer von cis-N-Methyl-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-naphthalinamin ist.
10. Pharmazeutische Zusammenstellung, umfassend eine Verbindung, wie in irgend einem der Ansprüche 1 bis 8 beansprucht, in einer zum Bekämpfen seelischer Depression als essentieller, aktiver Bestandteil wirksamen Menge, zusammen mit einem pharmazeutisch annehmbaren Verdünnungsmittel oder Träger.
HK822/84A 1979-11-01 1984-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof HK82284A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/090,240 US4536518A (en) 1979-11-01 1979-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Publications (1)

Publication Number Publication Date
HK82284A true HK82284A (en) 1984-11-09

Family

ID=22221931

Family Applications (1)

Application Number Title Priority Date Filing Date
HK822/84A HK82284A (en) 1979-11-01 1984-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof

Country Status (38)

Country Link
US (1) US4536518A (de)
EP (1) EP0030081B1 (de)
JP (1) JPS605584B2 (de)
KR (2) KR840002001B1 (de)
AT (1) ATE2668T1 (de)
AU (1) AU517357B2 (de)
BA (2) BA97149B1 (de)
BG (1) BG60333B2 (de)
CA (1) CA1130815A (de)
CS (4) CS238609B2 (de)
DD (2) DD155615A5 (de)
DE (2) DE3062225D1 (de)
DK (1) DK153390C (de)
EG (1) EG15527A (de)
ES (2) ES496443A0 (de)
FI (1) FI68806C (de)
GR (1) GR70781B (de)
HK (1) HK82284A (de)
HR (2) HRP930199B1 (de)
HU (1) HU182224B (de)
IE (1) IE50395B1 (de)
IL (1) IL61374A (de)
IN (2) IN159643B (de)
LU (1) LU88330I2 (de)
LV (2) LV5456A3 (de)
MX (1) MX5980E (de)
MY (1) MY8500326A (de)
NL (1) NL940018I1 (de)
NO (2) NO148996C (de)
NZ (1) NZ195407A (de)
PH (1) PH17319A (de)
PT (1) PT72004B (de)
SG (1) SG56584G (de)
SI (2) SI8012798A8 (de)
SU (2) SU1014467A3 (de)
UA (2) UA6301A1 (de)
YU (2) YU41951B (de)
ZA (1) ZA806726B (de)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4839104A (en) * 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
FR2623802B1 (fr) * 1987-11-26 1990-05-04 Lucien Laboratoires Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
US4855500A (en) * 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
FR2632633B1 (fr) * 1988-06-08 1991-04-05 Delalande Sa Procede de preparation de 4-aryl-1-tetralones
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
FR2665443B1 (fr) * 1990-08-03 1992-11-06 Lucien Laboratoires Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
US5082970A (en) * 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
GB9114947D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5196607A (en) * 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5288916A (en) * 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
DE69406553T2 (de) * 1993-11-30 1998-02-26 Pfizer Inc., New York, N.Y. Verfahren zur herstellung von chiralen tetralonen
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (de) * 1995-08-16 2000-04-26 Eli Lilly And Company Potenzierung von Serotonin-Wirkstoffresponz
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) * 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
EP0999830A1 (de) * 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salze und dozierungsformen für dauerverabreichung enthaltend sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
IN191358B (de) * 1998-01-16 2003-11-29 Pfizer Prod Inc
WO1999046233A1 (en) * 1998-03-09 1999-09-16 Sumika Fine Chemicals Co., Ltd. Benzyl alcohol derivatives
HUP0101322A3 (en) * 1998-03-18 2002-06-28 Ciba Sc Holding Ag Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
FR2777000B1 (fr) 1998-04-01 2002-09-27 Catalys Procede de preparation de la sertraline racemique
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
US6054614A (en) * 1998-04-23 2000-04-25 Ciba Specialty Chemicals Corporation Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
HU226423B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing a 1(2h)-naphtalene-1-ylidene derivative
IN182588B (de) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
BR9914418A (pt) * 1998-10-13 2001-06-26 Pfizer Prod Inc Concentrado oral de sertralina
IL132500A0 (en) 1998-10-29 2001-03-19 Pfizer Prod Inc Stereoselective microbial reduction of a racemic tetralone
AU1031500A (en) * 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
EP1133459B1 (de) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form v
EP1632472A1 (de) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd Polymorphe des Sertralin-Hydrochlorids
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
AU2315400A (en) * 1999-03-01 2000-09-21 Middleton, Donald Stuart 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6593496B1 (en) * 1999-06-09 2003-07-15 Pfizer Inc Process for preparing sertraline from chiral tetralone
US6720454B1 (en) * 1999-07-29 2004-04-13 Ciba Specialty Chemicals Corporation Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
IN185109B (de) * 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
DK174219B1 (da) * 1999-10-27 2002-09-30 Gea Farmaceutisk Fabrik As Forbedret syntese af racemisk sertralin
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
HUP0203384A3 (en) * 1999-11-16 2006-02-28 Ciba Sc Holding Ag Process for the preparation of ketimines
IL149527A0 (en) * 1999-11-16 2002-11-10 Ciba Sc Holding Ag Process for the preparation of ketimines
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
ATE354358T1 (de) 1999-12-21 2007-03-15 Teva Pharma Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
IN187170B (de) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
WO2001068566A1 (en) * 2000-03-14 2001-09-20 Teva Pharmaceutical Industries Ltd. Novel process for preparing (+)-cis-sertraline
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
IN192343B (de) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
DE60119047D1 (de) * 2000-08-31 2006-06-01 Pfizer Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1397343A1 (de) * 2001-05-31 2004-03-17 Orion Corporation Fermion Verfahren zur herstellung der polymorphen form ii von sertralinhydrochlorid
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
CA2448499A1 (en) * 2001-06-15 2002-12-27 Orion Corporation Fermion A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
AU2003251290A1 (en) * 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
AU2003254475A1 (en) * 2002-07-29 2004-02-16 Cipla Limited Sertraline
PL376832A1 (pl) * 2002-11-07 2006-01-09 Torrent Pharmaceuticals Ltd. Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
WO2004087732A2 (en) * 2003-03-11 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
US7276629B2 (en) * 2003-04-14 2007-10-02 Teva Pharmaceutical Industries Ltd. Hydrogenation of imine intermediates of sertraline with catalysts
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US7189876B2 (en) * 2003-07-15 2007-03-13 Recordati Industria Chimica E Farmaceutica S.P.A. Methods for preparing sertraline hydrochloride polymorphs
WO2005012224A1 (en) * 2003-07-15 2005-02-10 Recordati Industria Chimica E Farmaceutica S.P.A. Sertraline hydrochloride form ii and methods for the preparation thereof
HU227495B1 (en) * 2003-07-21 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing of imine intermediate
WO2005023752A2 (en) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd. A recycling process for preparing sertraline
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
SI1668014T1 (sl) * 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
EP1682483B1 (de) * 2003-11-04 2010-05-26 Cipla Ltd. Verfahren zur herstellung von polymorphen von sertralin hydrochlorid
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
TW200640836A (en) * 2005-02-23 2006-12-01 Teva Pharma Processes for preparing sertraline
EP1868434A4 (de) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc Beta-lactamylalkansäuren zur behandlung von prämenstruellen störungen
JP2006265169A (ja) * 2005-03-24 2006-10-05 Tokuyama Corp アルキリデンコハク酸化合物の製造方法
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
TW200716595A (en) * 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
CA2576097C (en) * 2005-06-03 2009-10-27 Hetero Drugs Limited A highly stereoselective synthesis of sertraline
US20070100165A1 (en) * 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
SG163588A1 (en) 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
WO2007119247A2 (en) * 2006-04-17 2007-10-25 Unichem Laboratories Limited Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
TR200808115T1 (tr) * 2006-04-28 2009-03-23 Sandoz Ag 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20100279990A1 (en) * 2006-06-13 2010-11-04 Ramot At Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9260413B2 (en) * 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP2380595A1 (de) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Zusammensetzungen und Verfahren zur selektiven Abgabe von Oligonukleotidmolekülen an spezifische Neuronentypen
US8440655B2 (en) 2010-06-21 2013-05-14 Theracos, Inc. Combination therapy for the treatment of diabetes
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101340270B1 (ko) * 2011-11-10 2013-12-10 보령제약 주식회사 (+)-시스-서트랄린의 선택적인 제조방법
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
MX2021005502A (es) 2014-03-28 2023-01-16 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
US10266481B2 (en) 2014-06-20 2019-04-23 Council Of Scientific & Industrial Research Organocatalytic asymmetric synthesis of antidepressants
JP6695323B2 (ja) * 2014-08-11 2020-05-20 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180345B1 (de) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- und furo[2,3-d]pyrimidin-2,4[1h,3h]-dion derivate als trpc5 modulatoren zur behandlung von neuropsychiatrischen erkrankungen
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
EP4166237A1 (de) 2015-09-21 2023-04-19 S.C. Johnson & Son, Inc. Misch- und abgabesystem
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
WO2020043716A1 (en) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis
GB2630572A (en) 2023-05-29 2024-12-04 Novumgen Ltd An orally disintegrating tablet of sertraline and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887509A (en) * 1956-11-05 1959-05-19 Lilly Co Eli Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds

Also Published As

Publication number Publication date
KR840002000B1 (ko) 1984-10-27
FI803398L (fi) 1981-05-02
DD155615A5 (de) 1982-06-23
BG60333B2 (bg) 1994-11-30
YU42846B (en) 1988-12-31
IE50395B1 (en) 1986-04-16
IN159644B (de) 1987-05-30
CS238617B2 (en) 1985-12-16
HRP930199B1 (en) 1996-02-29
IN159643B (de) 1987-05-30
IL61374A (en) 1983-10-31
ES8201949A1 (es) 1982-01-16
YU67283A (en) 1983-10-31
CA1130815A (en) 1982-08-31
BA97150B1 (bs) 1998-12-28
IL61374A0 (en) 1980-12-31
NO1996011I1 (no) 1996-09-24
DE19775012I2 (de) 2001-02-08
PH17319A (en) 1984-07-20
MX5980E (es) 1984-09-12
UA6311A1 (uk) 1994-12-29
ZA806726B (en) 1981-10-28
JPS605584B2 (ja) 1985-02-12
CS238618B2 (en) 1985-12-16
NO148996B (no) 1983-10-17
NO148996C (no) 1984-01-25
NL940018I1 (nl) 1994-10-17
SI8012798A8 (sl) 1994-12-31
CS354291A3 (en) 1992-12-16
GR70781B (de) 1983-03-23
DK153390B (da) 1988-07-11
ES496443A0 (es) 1982-01-16
LV5457A3 (lv) 1994-03-10
SU1034602A3 (ru) 1983-08-07
YU279880A (en) 1983-09-30
SG56584G (en) 1985-03-08
DD203045A5 (de) 1983-10-12
DK153390C (da) 1988-12-05
IE802259L (en) 1981-05-01
NO803258L (no) 1981-05-04
UA6301A1 (uk) 1994-12-29
EG15527A (en) 1987-04-30
ATE2668T1 (de) 1986-03-15
LU88330I2 (fr) 1994-05-04
FI68806C (fi) 1985-11-11
ES8207123A1 (es) 1982-09-01
EP0030081B1 (de) 1983-03-02
CS238609B2 (en) 1985-12-16
ES506892A0 (es) 1982-09-01
KR830004202A (ko) 1983-07-06
NZ195407A (en) 1984-05-31
PT72004A (en) 1980-11-01
HRP931527B1 (en) 1996-04-30
SU1014467A3 (ru) 1983-04-23
SI8310672A8 (en) 1996-04-30
YU41951B (en) 1988-02-29
DE3062225D1 (en) 1983-04-07
DK395280A (da) 1981-05-02
HU182224B (en) 1983-12-28
JPS5686137A (en) 1981-07-13
BA97149B1 (bs) 1998-12-28
US4536518A (en) 1985-08-20
AU517357B2 (en) 1981-07-23
MY8500326A (en) 1985-12-31
KR840002001B1 (ko) 1984-10-27
AU6389780A (en) 1981-05-07
LV5456A3 (lv) 1994-03-10
PT72004B (en) 1981-08-31
FI68806B (fi) 1985-07-31
EP0030081A1 (de) 1981-06-10

Similar Documents

Publication Publication Date Title
EP0030081B1 (de) Antidepressiv wirkende Derivate des cis-4-Phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische Zusammensetzungen daraus
EP0028901B1 (de) Antidepressiv wirkende Derivate des trans-4-Phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische Zusammensetzungen daraus
Welch et al. Nontricyclic antidepressant agents derived from cis-and trans-1-amino-4-aryltetralins
US3637740A (en) Aminobenzocycloalkane compounds
US4313896A (en) Aryloxyphenylpropylamines
NO319078B1 (no) Fremgangsmate for fremstilling av racemisk sertralin, samt mellomprodukter ved fremstillingen
EP0012643B1 (de) 1-Phenyl-3-(4-piperidyl)-propan-1-on-Derivate, Verfahren zu ihrer Herstellung und die enthaltende pharmazeutische Zusammensetzungen
EP0009800A2 (de) 4-Phenyl-1,3-benzodiazepine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und diese Verbindungen zur Verwendung als Arzneimittel
US4309424A (en) 4-Phenyl-1,3-benzodiazepines
FR2769312A1 (fr) Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0076669A1 (de) 3-Phenyl-1-indanamine, pharmazeutische Zusammensetzungen und Verfahren zu ihrer Herstellung
JPS59497B2 (ja) トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
JPS58157767A (ja) ６−クロロ−７，８−ジヒドロキシ−１−（４−ヒドロキシフエニル）−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンのｒ−オヨビｓ−異性体
US4003936A (en) 2-Hydrocinnampyl-1,3-cyclopentanediones
CA1147735A (en) Aroylethenylpiperidinobutyrophenone antipsychotic agents
PL129248B1 (en) Method of preparation of novel cis isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtaleneamine
US3497557A (en) 3,4,5,6,7,8-hexahydro-2(1h)-naphthalenones
PL130600B1 (en) Process for preparing novel cis-isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamine

Legal Events

Date Code Title Description
PE Patent expired